Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Testis expressed transcript, Y-linked 22 (TTTY22)
- Target
- TTTY22
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein coding RNA, Y-chromosome gene
01
Overview
Testis expressed transcript, Y-linked 22 (TTTY22) is a long non-coding RNA (lncRNA) gene located on the Y chromosome in humans[1][2][3][5]. It is also known by the synonym NCRNA00147. TTTY22 is classified as a non-protein coding RNA and is part of a set of Y-linked transcripts that are primarily or exclusively expressed in the testis. While long non-coding RNAs can play roles in chromatin remodeling, sponging of microRNAs, and regulation of gene expression[4][6], there are no direct data describing a specific biological function, disease mechanism, or established role as a drug target for TTTY22. It is not considered a receptor, enzyme, or transporter, nor is it a therapeutic target. Some data have described associations with endometriosis[2], but no clinical or mechanistic validation as a biomarker or therapeutic target is available.
- Other names
- NCRNA00147Non-protein coding RNA 147Testis-specific transcript, Y-linked 22 (non-protein coding)NCRNA00147, testis-specific transcript, Y-linked 22 (non-protein coding)TTTY22
02
Mechanism of action
Not applicable; no drugs known to target TTTY22
03
Biological functions
Likely involved in regulation of gene expression at the RNA level, based on classification as a long non-coding RNA (functions such as chromatin remodeling, transcriptional and post-transcriptional regulation are typical for lncRNAs)Specific biological function for TTTY22 is not described in available sources
04
Disease associations
Endometriosis (association listed, but not established as a driver or biomarker)No definitive evidence for major disease implications (such as cancer or inflammatory disease) as a primary factor
05
Safety considerations
None reported; as a long non-coding RNA, direct therapeutic targeting and safety are not described
06
Interacting drugs
None reported
07
Biomarkers
None identified for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Testis expressed transcript, Y-linked 22 (TTTY22).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Testis expressed transcript, Y-linked 22 (TTTY22).